wedge
REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm
REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm BIOTROFIX - Premier Preclinical CRO - Stroke, Alzheimer's, ALS, TBI Research - Seth P. Finklestein, M.D., CEO REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm Finklestein SP references, publications, articles on preclinical research, drug development, cardiac disease and preclinical drug discovery - Seth P. Finklestein M.D.
REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm
 
Home
greybar
The Company
greybar
Preclinical Research Services
PK/PD Studies
Acute Stroke
Stroke Recovery
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Traumatic Brain Injury
Spinal Cord Injury
Muscular Dystrophy
Myocardial Infarction
Peripheral Vascular Disease
Others
Will Travel Services
greybar
The Team
greybar
News from Biotrofix
greybar
Publications
greybar
Contact Us


Well-equipped CRO laboratory
 

Effect of basic fibroblast growth factor treatment ...

1. Stroke. 2003 Nov;34(11):2722-8. Epub 2003 Oct 23.

Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats.

Wada K, Sugimori H, Bhide PG, Moskowitz MA, Finklestein SP.

Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA.

BACKGROUND AND PURPOSE: Intracisternal basic fibroblast growth factor (bFGF) enhances sensorimotor recovery after focal cerebral infarction in rats. One possible mechanism is stimulation of endogenous progenitor cells in brain. We investigated the effects of intracisternal bFGF on brain progenitor cells after stroke.

METHODS: Proliferating brain cells were labeled with bromodeoxyuridine (BrdU) before middle cerebral artery (MCA) occlusion or sham surgery in rats. bFGF (0.5 microg) or vehicle was administered intracisternally at 24 and 48 hours after MCA occlusion, and rats were killed at 7, 14, or 21 days after stroke.

Immunohistochemistry for BrdU and neuron- or astrocyte-specific markers was used to characterize progenitor cells and their progeny in the subventricular zone and dentate gyrus of the hippocampus.

RESULTS: Infarct size did not differ among rats with or without bFGF treatment. MCA occlusion alone increased the number of BrdU-labeled cells in the ipsilateral subventricular zone at days 7 to 21, and there was a trend toward increased cell proliferation with bFGF treatment. In the dentate gyrus, the number of BrdU-labeled cells was increased bilaterally after MCA occlusion (peak at day 7). This increase was greater after bFGF treatment. In the subventricular zone, 30% of BrdU-labeled cells were immunopositive for the immature neuron-specific marker
doublecortin at day 7, and their number declined to 2% at day 21. In the dentate gyrus, the majority of BrdU-labeled cells colabeled with doublecortin at day 7, becoming NeuN positive at day 21.

CONCLUSIONS: Stroke produces significant changes in progenitor cells in brain that are augmented by bFGF treatment.

PMID: 14576381 [PubMed - indexed for MEDLINE]

 

 
 
Home | The Company | Preclinical Research Services | The Team | News | Publications | Contact Us | Site Map
wedgeBiotrofix, Inc. 604 Webster Street, Needham, MA 02494 Tel: 781-786-8890 Fax: 781-465-6061


Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.